Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent

Group 1 - The article introduces Monopar Therapeutics Inc. (NASDAQ: MNPR) and highlights its business overview as provided in its Q2 2025 report [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to watch and buy/sell ratings [1] - The group also provides forecasts for product sales and integrated financial statements for major pharmaceutical companies, along with discounted cash flow analysis and market-by-market analysis [1] Group 2 - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [1]